{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:33:57Z","timestamp":1740123237631,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["5746604"],"award-info":[{"award-number":["5746604"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We questioned whether a history of negative screening outcomes could be used to predict breast cancer risk, and thus be used as a potential factor for stratification of mammographic screening. Data from the Norwegian population based breast cancer screening program, BreastScreen Norway, was used to estimate cumulative hazard rates for breast cancer by number of prior negative screening outcomes among participants from 1995 through 2016. We followed three age cohorts of women, who started screening at age 50\u201354, 55\u201359, and 60\u201364\u00a0years. Further, we estimated the absolute and relative risk of breast cancer by number of prior negative screening outcomes. The cumulative hazard curves were parallel for all numbers of negative screening outcomes for all age cohorts. The absolute risk of breast cancer increased with number of negative screening outcomes for the youngest age cohort. For the oldest age cohorts, the absolute risk was stable during the screening period and decreased thereafter. The number of negative screening outcomes was not associated with risk of breast cancer, adjusted for age, percent screening attendance and calendar years (HR 1.00, 95% CI 0.98\u20131.02). Our results suggest that the number of negative screening outcomes does not predict breast cancer risk among participants in BreastScreen Norway.<\/jats:p>","DOI":"10.1007\/s10654-020-00645-0","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T14:51:48Z","timestamp":1589899908000},"page":"549-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Number of prior negative screening outcomes does not influence future risk of breast cancer"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-7851","authenticated-orcid":false,"given":"Marie","family":"Lilleborge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-3492","authenticated-orcid":false,"given":"Ragnhild S.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-8939","authenticated-orcid":false,"given":"Solveig","family":"Hofvind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"issue":"3","key":"645_CR1","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/bcr3427","volume":"15","author":"SW Duffy","year":"2013","unstructured":"Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res. 2013;15(3):R41. https:\/\/doi.org\/10.1186\/bcr3427.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"645_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.maturitas.2014.09.002","volume":"79","author":"H Depypere","year":"2014","unstructured":"Depypere H, Desreux J, P\u00e9rez-L\u00f3pez FR, et al. EMAS position statement: individualized breast cancer screening versus population-based mammography screening programmes. Maturitas. 2014;79(4):481\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2014.09.002.","journal-title":"Maturitas"},{"issue":"3","key":"645_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.maturitas.2012.08.004","volume":"73","author":"J Desreux","year":"2012","unstructured":"Desreux J, Bleret V, Lifrange E. Should we individualize breast cancer screening? Maturitas. 2012;73(3):202\u20135. https:\/\/doi.org\/10.1016\/j.maturitas.2012.08.004.","journal-title":"Maturitas"},{"issue":"1","key":"645_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/0003-4819-155-1-201107050-00003","volume":"155","author":"JT Schousboe","year":"2011","unstructured":"Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155(1):10\u201320. https:\/\/doi.org\/10.7326\/0003-4819-155-1-201107050-00003.","journal-title":"Ann Intern Med"},{"issue":"6","key":"645_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/oxfordjournals.aje.a113705","volume":"118","author":"SD Walter","year":"1983","unstructured":"Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983;118(6):865\u20136. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a113705.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"645_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10654-014-9972-6","volume":"30","author":"SB Andersen","year":"2015","unstructured":"Andersen SB, T\u00f6rnberg S, Kilpel\u00e4inen S, Von Euler-Chelpin M, Njor SH. Is mammography screening history a predictor of future breast cancer risk? Eur J Epidemiol. 2015;30(2):143\u20139. https:\/\/doi.org\/10.1007\/s10654-014-9972-6.","journal-title":"Eur J Epidemiol"},{"key":"645_CR7","unstructured":"Hofvind S, Tsuruda K, Mangerud G, et al. The Norwegian Breast Cancer Screening Program, 1996\u20132016: Celebrating 20\u00a0years of organised mammographic screening. In: Cancer in Norway 2016\u2014Cancer incidence, mortality, survival and prevalence in Norway. 2017. https:\/\/www.kreftregisteret.no\/globalassets\/cancer-in-norway\/2016\/mammo_cin2016_special_issue_web.pdf. Accessed 03 Feb 2020."},{"issue":"7","key":"645_CR8","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","volume":"45","author":"IK Larsen","year":"2009","unstructured":"Larsen IK, Sm\u00e5stuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.037.","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-020-00645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-020-00645-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-020-00645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T23:54:32Z","timestamp":1621382072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-020-00645-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s10654-020-00645-0","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"type":"print","value":"0393-2990"},{"type":"electronic","value":"1573-7284"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"10 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was entirely based on data from the Cancer Registry of Norway. No contact was made with patients, relatives or their doctors. By law, all cancer cases in Norway are reported to the Cancer Registry of Norway. In BreastScreen Norway, 98% of women screened have approved for their data to be used for research and quality control.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}